In the BioHarmony Drug Report Database
Midazolam, Nayzilam, Buccolam (midazolam maleate) is a small molecule pharmaceutical. Midazolam maleate was first approved as Midazolam on 2011-09-04. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy. It is known to target Alpha-1B adrenergic receptor. Buccolam’s patents are valid until 2038-06-20 (FDA).
Image (chem structure or protein)